-+ 0.00%
-+ 0.00%
-+ 0.00%

GRI Bio presents late-breaking Phase 2a GRI-0621 idiopathic pulmonary fibrosis data at ERS 2026

PUBT·08/24/2026 13:05:24
Listen to the news
GRI Bio presents late-breaking Phase 2a GRI-0621 idiopathic pulmonary fibrosis data at ERS 2026
  • Gri Bio flagged new Phase 2a data for oral IPF drug GRI-0621 for future presentation at the ERS Congress on Sept. 6, 2026.
  • Disclosed outcomes pointed to improved lung function signals, anti-fibrotic biomarker shifts, and favorable tolerability versus placebo.
  • Program positioning centers on a differentiated RARβ/γ-selective mechanism, supporting continued clinical advancement in idiopathic pulmonary fibrosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240905PRIMZONEFULLFEED9814662) on August 24, 2026, and is solely responsible for the information contained therein.